Business Context and Reporting Period
This Form 8-K is a current report filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on July 19, 2019, with the earliest event reported on that date. The filing primarily addresses the completion of an asset sale and a change in the company's independent registered public accounting firm.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or margin data. The only specific financial figure disclosed relates to a transaction:
- Asset Sale Proceeds: $320,000 (subject to adjustments) for the sale of assets related to the HOTSHOT business.
- Debt and Liquidity: The filing text does not provide clear values for debt levels or liquidity positions.
Material Changes
- Asset Disposition: On July 24, 2019, Salarius completed the sale of specified assets (contracts, inventory, goodwill, and intangible assets) related to its HOTSHOT business to Cliff-Cartwright Corporation.
- Accounting Firm Change: On July 19, 2019, the company dismissed Weaver & Tidwell, L.L.P. and engaged Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2019.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, revenue outlook, or management commentary regarding future financial performance. Regarding risks and contingencies:
- Accountant Transition: The company confirmed there were no disagreements with the former accountant (Weaver & Tidwell) regarding accounting principles, practices, or audit scope during the years ended December 31, 2018 and 2017.
- Transaction Terms: The asset sale is subject to customary representations, warranties, and covenants, with no material relationship between the parties other than the agreement itself.
Investor Verification Checklist
- Verify the exact nature of the "adjustments" to the $320,000 sale price in the attached Asset Purchase Agreement (Exhibit 2.1).
- Confirm the impact of the HOTSHOT asset divestiture on the company's remaining operational pipeline and future revenue streams.
- Review the letter from the former accountant (Exhibit 16.1) to ensure no undisclosed reportable events occurred.
- Check subsequent filings for the first financial statements audited by Ernst & Young LLP to assess any changes in accounting treatment.